Barrett's Esophagus Patient Registry

Massachusetts General Hospital750 enrolled

Overview

The ultimate goal of the Barrett's Esophagus Patient Registry is to help develop more effective targeted screening strategies and treatment options for Barrett's esophagus and esophageal adenocarcinoma (EAC). We plan to do by developing a registry that will serve as a platform. Examples of analyses could include identifying genetic determinants and biomarkers that predict BE, progression of BE to EAC, as well as the response to therapies.

Study Type

OBSERVATIONAL

Enrollment

750

Conditions

Barrett Esophagus Esophageal Adenocarcinoma Gastroesophageal Reflux

Eligibility

Sex: ALLMin age: 18 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * Barrett's (BE): Patients who have Barrett's esophagus (all stages: Barrett's metaplasia, low-grade dysplasia, high-grade dysplasia) based upon standard endoscopic and histologic criteria. * Adenocarcinoma (EAC): Patients who have esophageal adenocarcinoma. * The control cohort will include patients ages 18 and older with no prior history of BE and EAC. These may include patients who are being seen or have been previously seen at MGH GI Associates for conditions including gastroesophageal reflux disease, peptic esophagitis, eosinophilic esophagitis, esophageal motility disorders such as achalasia and nutcracker esophagus. Exclusion Criteria: * Inability or unwillingness to provide blood samples. * History of known bleeding disorders. * Currently awaiting organ transplantation. * Having an acute or severe chronic illness such as congestive heart failure or any other condition that would prohibit performing the endoscopy.

Locations (1)

Massachusetts General Hospital

Boston, Massachusetts, United States

RECRUITING

Outcomes

Primary Outcomes

Progression to esophageal adenocarcinoma

Time frame: 5 years (on average although follow-up will continue)

Secondary Outcomes

Identify and validate genetic determinants that predict progression of BE to EAC and predict response to BE therapy

Time frame: 5 years on average

Evaluate the natural history of BE with and without treatment based on clinical, functional and economic outcomes of the cases

Time frame: 5 years on average

Central Contacts

Katherine Perzan, BA

CONTACT

617-726-1431 kperzan@partners.org

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.